Skip to main content
    V

    Vir Biotechnology Inc (VIR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.58
    -0.38 (-3.82%)

    Market Cap: $1.71B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vir Biotechnology Inc (VIR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Vir Biotechnology (VIR) to earn -$1.00 per share in the fiscal year ending Dec 31, 2026, on revenue of $330.33M. Of 9 analysts, 9 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy333.3%
    Buy666.7%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 79.8%.

    Fiscal year ending Dec 31, 2026
    -$1.00
    EPS consensus, revenue $330.33M
    Fiscal year ending Dec 31, 2027
    -$2.39
    EPS consensus, revenue $66.74M
    Next report
    Feb 22, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.00-$1.75 to -$0.078$330.33M$238.80M to $543.72M8
    Dec 31, 2027-$2.39-$2.84 to -$1.927$66.74M$2.00M to $156.75M7

    Quarterly Estimates

    The EPS consensus rises from -$0.53 for the quarter ending Dec 31, 2026 to -$0.44 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.53-$0.71 to -$0.1010$28.83M$1.96M to $69.09M8
    Mar 31, 2027-$0.44-$0.66 to -$0.314$17.00M$500000 to $50.01M3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 5 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202620
    Fiscal year ending Dec 31, 202721
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.78.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.00-$1.77-$1.76-$1.76-$1.78N/A
    Fiscal year ending Dec 31, 2027-$2.39-$2.47-$2.49-$2.49-$2.49N/A
    Quarter ending Mar 31, 2027-$0.44-$0.49-$0.43-$0.43-$0.47N/A

    Frequently Asked Questions About VIR

    What is the VIR stock forecast?

    Consensus analyst estimates put Vir Biotechnology's EPS at -$1.00 for the fiscal year ending Dec 31, 2026, on revenue of $330.33M. The consensus rating from 9 analysts is Buy.

    How do analysts rate VIR stock?

    Of 9 analysts covering Vir Biotechnology, 3 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from VIR next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.00, with estimates from -$1.75 to -$0.07 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.39, with estimates from -$2.84 to -$1.92 from 7 analysts.

    What revenue do analysts expect from Vir Biotechnology next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $330.33M, with estimates from $238.80M to $543.72M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $66.74M, with estimates from $2.00M to $156.75M.

    How many analysts cover VIR?

    9 analysts rate Vir Biotechnology stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.